Exploring the Efficacy of Botulinum Toxin Type A in Pediatric Generalized Dystonia, an Uncommon Use: A Colombian Case Series
DOI:
https://doi.org/10.17533/udea.iatreia.288Keywords:
Botulinum toxins, Case Reports, Cerebral palsy, DystoniaAbstract
Introduction: Botulinum toxin (BoNT) is used in focal dystonias. Generalized dystonia is often refractory to conventional treatment.
Objectives: This article aims to describe the clinical outcome of BoNT in pediatric patients with generalized dystonia, based on its potential consideration as a therapeutic strategy.
Methods: Description of 4 patients (aged 7-13 years) with generalized dystonia, refractory to initial pharmacological management, in whom BoNT-A was considered as treatment. Informed consent was obtained from caregivers/patients for the use of clinical records.
Results: All patients were treated with BoNT-A (17-30 IU/kg), with the biceps brachii being the most frequently injected site, followed by the splenius capitis.
Conclusions: BoNT is a well-established treatment in adults with focal dystonia. Pediatric data supporting its use is limited, especially in generalized dystonias. However, improvements in motor function and comorbidities have been observed, considering it a safe and theoretically justified option, especially in cases unresponsive to other treatments.
Downloads
References
(1) Jain R, Pandey S, Raghav S. Movement Disorders in Children. Indian Pediatr [Internet]. 2021;58(9):861-870. Disponible en: https://www.indianpediatrics.net/sep2021/sep-861-870.htm
(2) Pana A, Saggu BM. Dystonia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://pubmed.ncbi.nlm.nih.gov/28846290/
(3) Lumsden DE. Spastic dystonia: Still a valid term. Dev Med Child Neurol [Internet]. 2023;65(10):1308-1315. https://doi.org/10.1111/dmcn.15582
(4) Pringsheim T, Batla A, Shalash A, Sahu JK, Cosentino C, Ebrahimi-Fakhari D, et al. Transitional Care for Young People with Movement Disorders: Consensus-Based Recommendations from the MDS Task Force on Pediatrics. Mov Disord Clin Pract [Internet]. 2023;10(5):748-755. https://doi.org/10.1002/mdc3.13728
(5) Stephen CD, Dy-Hollins M, Melo-De Gusmao C, Al Qahtani X, Sharma N. Dystonias: Clinical Recognition and the Role of Additional Diagnostic Testing. Semin Neurol [Internet]. 2023;43(1):17–34. https://doi.org/10.1055/s-0043-1764292
(6) Bohn E, Goren K, Switzer L, Falck-Ytter Y, Fehlings D. Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis. Dev Med Child Neurol [Internet]. 2021;63(9):1038–50. https://doi.org/10.1111/dmcn.14874
(7) Gorodetsky C, Fasano A. Approach to the Treatment of Pediatric Dystonia. Dystonia [Internet]. 2022;1(10287). https://doi.org/10.3389/dyst.2022.10287
(8) Kumar VN, Garg D, Mukherjee SB, Pandey S, Sharma S. Clinical and Etiological Profile of Dystonia among Children. Indian J Pediatr [Internet]. 2023;90(12):1267. https://doi.org/10.1007/s12098-023-04719-1
(9) Jinnah HA. The Dystonias. Continuum (Minneap Minn) [Internet]. 2019;25(4):976-1000. https://doi.org/10.1212/CON.0000000000000747
(10) Brandsma R, van Egmond ME, Tijssen MAJ, Eggink H, Gelauff JM, Koens LH, et al. Diagnostic approach to paediatric movement disorders: a clinical practice guide. Dev Med Child Neurol [Internet]. 2021;63(3):252–8. https://doi.org/10.1111/dmcn.14721
(11) Dressler D, Altavista MC, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm [Internet]. 2021;128(3):321–35. https://doi.org/10.1111/dmcn.14721
(12) Russ JB, Nallappan AM, Robichaux-Viehoever A. Management of Pediatric Movement Disorders: Present and Future. Semin Pediatr Neurol [Internet]. 2018;25:136–51. https://doi.org/10.1016/j.spen.2018.02.004
(13) Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol [Internet]. 2011;18(1):5–18. https://doi.org/10.1111/j.1468-1331.2010.03042.x
(14) van Ermengem E. On a new anaerobic bacillus and its relation to botulism. J Hyg Infect Dis [Internet]. 1897;26(1):1–56.
(15) Scott AB. Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery. Ophthalmology [Internet]. 1980;87(10):1044–9. https://doi.org/10.1016/S0161-6420(80)35127-0
(16) Marques JRS. Toxina botulunica A [Internet]. 2021. Pediamécum Asoc Española pediatría. Disponible en: https://www.aeped.es/comite-medicamentos/pediamecum/toxina-botulinica
(17) Ferreira-Camargo CH, Ghizoni-Teive HA. Use of botulinum toxin for movement disorders. Drugs Context [Internet]. 2019;8:1–14. https://doi.org/10.7573/dic.212586
(18) Gorodetsky C, Fasano A. Approach to the Treatment of Pediatric Dystonia. Dystonia [Internet]. 2022;1(10287):1–17. https://doi.org/10.3389/dyst.2022.10287
(19) Sätilä H. Over 25 years of pediatric botulinum toxin treatments: What have we learned from injection techniques, doses, dilutions, and recovery of repeated injections? Toxins (Basel) [Internet]. 2020;12(7):440. https://doi.org/10.3390/toxins12070440
(20) Kahraman A, Seyhan K, Değer Ü, Kutlutürk S, Mutlu A. Should botulinum toxin A injections be repeated in children with cerebral palsy? A systematic review. Dev Med Child Neurol [Internet]. 2016;58(9):910–7. https://doi.org/10.1111/dmcn.13135
(21) Dressler D, Adib-Saberi F, Rosales RL. Botulinum toxin therapy of dystonia. J Neural Transm [Internet]. 2021;128(4):531–7. https://doi.org/10.1007/s00702-020-02266-z
(22) Silva JP, Faria LV, Almeida RC, Medeiros YL, Guimarães LDA. Effectiveness and safety of botulinum toxin in comparison with surgery for drooling in pediatric patients with neurological disorders: a systematic review. Br J Oral Maxillofac Surg [Internet]. 2022;60(5):691-701. https://doi.org/10.1016/j.bjoms.2021.10.010
(23) Esper CD, Freeman A. Factor SA. Lingual protrusion dystonia: Frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord [Internet]. 2010;16(7):438-41. https://doi.org/10.1016/j.parkreldis.2010.04.007
(24) Awaad Y, Tayem H, Elgamal A, Coyne MF. Treatment of childhood myoclonus with botulinum toxin type A. J Child Neurol [Internet]. 1999;14(12):781-6. https://doi.org/10.1177/088307389901401203
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Iatreia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
